Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic Obstructive Pulmonary Disease (COPD) is characterized by a persistent blockage of airflow in the lungs, which results in abnormal sputum, more than a “smoker’s cough” or a chronic cough and breathlessness. Symptoms of COPD include, cough, breathlessness (shortness of breath) and wheezing, sputum, chest infections, weight loss, tiredness, and ankle swelling.

The global asthma and COPD market is estimated to account for US$ 30,710.2 Mn in terms of value in 2020 and is expected to reach US$ 42,608 Mn by the end of 2027.

Global Asthma and COPD Market: Drivers

Increasing prevalence of COPD is expected to propel growth of the global asthma and COPD market over the forecast period. For instance, according to a report by Global Initiative for Chronic Obstruction Disease’s 2018 report, COPD is expected to result in 4.5 million global deaths annually by 2030.

Moreover, increasing member of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.

Combination Therapies held dominant position in the global asthma and COPD market in 2019, accounting for 57.0% share in terms of value, followed by Bronchodilators and Anti-Inflammatories, respectively.

Figure 1. Global Asthma and COPD Market Share (%), by Value, by Drug Type, 2019

Asthma & COPD  | Coherent Market Insights

Global Asthma and COPD Market: Restraints

High cost of asthma treatment is expected to hinder growth of the market. For instance, the annual per-person medical cost of asthma is around US$ 4,000 in the U.S.

Moreover, asthma treatment is a long process and patients affected with the disease have to follow many precautions. Very often patients discontinue the treatment halfway because of high cost. This is also expected to limit the market growth. 

request-sample

Asthma and COPD Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 29,386.8 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.8% 2027 Value Projection: US$ 42,608.1 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Type:
    • Bronchodilators: Short Acting Bronchodilators, Long Acting Bronchodilators, Anticholinergics.
    • Anti-Inflammatories: Inhaled Corticosteroids, Anti-Leukotriene, Monoclonal Antibodies.
    • Combination Therapies
  • By Disease Type: Asthma, COPD.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores.
Companies covered:

AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

Growth Drivers:
  • High prevalence of respiratory diseases
  • Product launches
Restraints & Challenges:
  • Patent losses
  • High cost

The global asthma and COPD market was valued at US$ 29,386.8 Mn in 2019 and is forecast to reach a value of US$ 42,608.1 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.

Figure 2. Global Asthma and COPD Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

       Asthma & COPD  | Coherent Market Insights                

Market Trends/Key Takeaways

Major organizations are focused on offering guidelines regarding management of asthma during the Covid-19 pandemic. For instance, in July 2020, Asthma and Allergy Foundation of America released a comprehensive guide, the “COVID-19 and Asthma Toolkit for Schools” to help educators and families of children living with asthma navigate best methods to stay healthy for those returning to classrooms during the COVID-19 pandemic.

R&D of novel therapies is expected to propel growth of the global asthma and COPD market. For instance, the study, ‘Masitinib Significantly Decreases the Rate of Asthma Exacerbations in Patients with Severe Asthma Uncontrolled by Oral Corticosteroids: A Phase 3 Multicenter Study’, reported in June 2020, stated that Masitinib significantly reduced asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids compared with placebo treatment.

Global Asthma and COPD Market: Competitive Landscape

Major players operating in the global asthma and COPD market include, AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.

Global Asthma and COPD Market: Key Developments

Major players in the market are focused on R&D of new therapies to expand their product portfolio. For instance, in July 2020, AstraZeneca's results from the positive Phase III ETHOS trial were published in the New England Journal of Medicine. The study demonstrated that the triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) reduced the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe COPD.

Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, European Medicines Agency accepted GlaxoSmithKline plc’s regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults.

Asthma is a type of chronic respiratory disease, which is characterized by attacks of breathlessness and wheezing. Asthma can occur at any stage, though it is the most common disease in children. Asthma attacks are linked to respiratory infections and environmental factors such as allergens, tobacco, smoke, and indoor and outdoor pollution. Indoor pollution factors include mold, chemicals, strong odors, and house dust whereas outdoor pollution factors include air pollution, allergens, tobacco, and smoking. Such factors are responsible for development and exacerbation of asthma.

Restraints of the Global Asthma and COPD Market

Major factors hampering the growth of the asthma and COPD market during the forecast period constitutes of patent losses, and high costs.

Key features of the study:

  • This report provides in-depth analysis of the global asthma and COPD market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global asthma and COPD market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Asthma and COPD Market, By Drug Type:
    • Bronchodilators
      • Short Acting Bronchodilators
      • Long Acting Bronchodilators
      • Anticholinergics
    • Anti-Inflammatories
      • Inhaled Corticosteroids
      • Anti-Leukotriene
      • Monoclonal Antibodies
    • Combination Therapies
  • Global Asthma and COPD Market, By Disease Type:
    • Asthma
    • COPD
  • Global Asthma and COPD Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Drug Stores
  • Global Asthma and COPD Market, By Geography:
    • North America
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Bronchodilators
          • Short Acting Bronchodilators
          • Long Acting Bronchodilators
          • Anticholinergics
        • Anti-Inflammatories
          • Inhaled Corticosteroids
          • Anti-Leukotriene
          • Monoclonal Antibodies
        • Combination Therapies
      • By Disease Type
        • Asthma
        • COPD
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • AstraZeneca PLC*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Novartis AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Verona Pharma plc
    • Regeneron Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Asthma and COPD Market, By Drug Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Bronchodilators
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Short Acting Bronchodilators
        • Long Acting Bronchodilators
        • Anticholinergics
    • Anti-Inflammatories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Inhaled Corticosteroids
        • Anti-Leukotriene
        • Monoclonal Antibodies
    • Combination Therapies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Asthma and COPD Market, By Disease Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Asthma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • COPD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Asthma and COPD Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Drug Stores
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Asthma and COPD Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • AstraZeneca PLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Verona Pharma plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 27 figures on “Asthma and COPD Market – Global forecast to 2027.

Frequently Asked Questions

The global asthma and COPD market was valued at US$ 29,386.8 Mn in 2019 and is forecast to reach a value of US$ 42,608.1 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.
Major factor driving the growth of global asthma and COPD market during the forecast period include high prevalence of respiratory diseases, and product launches.
Major factors hampering the growth of the asthma and COPD market during the forecast period constitutes of patent losses, and high costs.
Combination therapies held dominant position in the global asthma and COPD market in 2019.
North America Asthma and COPD market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner